-0.21%
9.30%
6.16%
2.87%
3.84%
0.08%
-7.57%
AI Spotlight on BDX
Company Description
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.
The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products.The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Market Data
| Last Price | 247.97 |
| Change Percentage | -0.21% |
| Open | 247.86 |
| Previous Close | 248.49 |
| Market Cap ( Millions) | 71913 |
| Volume | 221458 |
| Year High | 250.91 |
| Year Low | 218.75 |
| M A 50 | 229.07 |
| M A 200 | 233.52 |
Financial Ratios
| FCF Yield | 4.27% |
| Dividend Yield | 1.57% |
| ROE | 5.15% |
| Debt / Equity | 35.10% |
| Net Debt / EBIDTA | 431.76% |
| Price To Book | 1.25 |
| Price Earnings Ratio | 41.61 |
| Price To FCF | 23.4 |
| Price To sales | 3.56 |
| EV / EBITDA | 21.2 |
News
- Jan -30 - Becton Dickinson (BDX) Reports Next Week: Wall Street Expects Earnings Growth
- Jan -28 - BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $750 Million Repurchase to Date in FY25
- Jan -24 - BD Stock Rises on Biosero Deal for AI-Powered Robotic Cytometry Tech
- Jan -24 - What Can The Dividend Kings Deliver In 2025?
- Jan -23 - BD and Biosero Collaborate to Enable Robotic Integration with Flow Cytometers Used in Drug Discovery and Development
- Jan -23 - BD and Biosero Collaborate to Enable Robotic Integration with Flow Cytometers Used in Drug Discovery and Development
- Jan -22 - Carilion Clinic First in Virginia to Offer Needle-free In-patient Blood Draws, Redefining Patient Standard of Care
- Jan -21 - Masimo names Becton Dickinson's Katie Szyman CEO
- Jan -17 - BDX or MMSI: Which Is the Better Value Stock Right Now?
- Jan -16 - BD to Announce Financial Results for its First Quarter of Fiscal 2025
- Jan -15 - Bet on 5 Top-Ranked Stocks With Rising P/E for Soild Gains
- Jan -15 - BD Boosts U.S. Manufacturing of Critical Medical Devices
- Jan -13 - New ASCCP Guidelines Include More Precise Method of Cervical Cancer Screening
- Jan -10 - BD Names Pamela Spikner as Chief Accounting Officer and Controller
- Jan -09 - New Survey Finds Women Are Skipping Their OB/GYN Exams, Increasing Risks for Cervical Cancer
- Jan -07 - BD To Host Virtual 2025 Annual Meeting of Shareholders
- Dec -31 - My Best Dividend Aristocrats For January 2025
- Dec -30 - 5 Top AI-in-MedTech Stocks for Big Gains in 2025: MDT, BSX & More
- Dec -18 - BDX Stock Down Despite New Expansion to Boost Fingertip Blood Testing
- Dec -17 - BD and Babson Diagnostics Launch Innovative Fingertip Blood Testing to Health Care Organizations
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Medical
Expected Growth : 4.5 %
What the company do ?
Medical from Becton, Dickinson and Company refers to the medical technology segment that develops, manufactures, and sells medical devices, instrument systems, and reagents.
Why we expect these perspectives ?
Becton, Dickinson and Company's Medical segment growth of 4.5% is driven by increasing demand for medication management and patient safety solutions, expansion in emerging markets, and strategic acquisitions. Additionally, the company's focus on innovation, particularly in the areas of diabetes care and infusion systems, contributes to its growth momentum.
Segment n°2 -> Life Sciences
Expected Growth : 4.8 %
What the company do ?
Life Sciences from Becton, Dickinson and Company provides research and clinical solutions for biological sample preparation, gene expression, and cellular analysis.
Why we expect these perspectives ?
Becton, Dickinson and Company's Life Sciences segment growth of 4.8% is driven by increasing demand for diagnostic solutions, expansion in emerging markets, and strategic acquisitions. Additionally, growth in molecular diagnostics, particularly in infectious disease testing, and increased adoption of automation and informatics solutions also contribute to this growth.
Segment n°3 -> Interventional
Expected Growth : 5.2 %
What the company do ?
Interventional from Becton, Dickinson and Company refers to minimally invasive medical devices and solutions for diagnosis and treatment of various diseases and conditions.
Why we expect these perspectives ?
The 5.2% growth in Interventional segment from Becton, Dickinson and Company is driven by increasing demand for minimally invasive procedures, innovative product launches, and strategic acquisitions. Additionally, expanding access to emerging markets, growing adoption of advanced technologies, and favorable reimbursement policies also contribute to this growth.
Becton, Dickinson And Company Products
| Product Range | What is it ? |
|---|---|
| Syringes | Single-use syringes for injecting medications, vaccines, and other fluids |
| Needles | Hypodermic needles for injecting medications, vaccines, and other fluids |
| Infusion Therapy | Devices and systems for delivering medications, fluids, and nutrients through infusion |
| Pharmaceutical Diagnostics | Diagnostic systems and tests for detecting and monitoring diseases |
| Microbiology | Systems and tests for detecting and identifying microorganisms |
| Molecular Diagnostics | Molecular diagnostic systems and tests for detecting and monitoring diseases |
| Biosciences | Research and discovery tools for life science research |
| Infection Prevention | Devices and systems for preventing and controlling infections |
| Surgical Instruments | Surgical instruments and systems for minimally invasive and open surgical procedures |
| Anesthesia Systems | Anesthesia delivery systems and accessories |
Becton, Dickinson and Company's Porter Forces
Threat Of Substitutes
The threat of substitutes for Becton, Dickinson and Company is medium due to the presence of alternative medical technologies and products that can replace their offerings.
Bargaining Power Of Customers
The bargaining power of customers for Becton, Dickinson and Company is low due to the company's strong brand reputation and the lack of buyer concentration in the medical technology industry.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Becton, Dickinson and Company is medium due to the presence of multiple suppliers and the company's ability to negotiate prices.
Threat Of New Entrants
The threat of new entrants for Becton, Dickinson and Company is low due to the high barriers to entry in the medical technology industry, including regulatory hurdles and high research and development costs.
Intensity Of Rivalry
The intensity of rivalry for Becton, Dickinson and Company is high due to the presence of several established competitors in the medical technology industry, leading to intense competition for market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 38.10% |
| Debt Cost | 3.95% |
| Equity Weight | 61.90% |
| Equity Cost | 6.29% |
| WACC | 5.40% |
| Leverage | 61.56% |
Becton, Dickinson and Company : Quality Control
Becton, Dickinson and Company passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| ISRG | Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and … |
| WST | West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. … |
| UNH | UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment … |
| RMD | ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as … |
| TMO | Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
ResMed
A-Score
1-Year Total Return ->
🥈
UnitedHealth
A-Score
1-Year Total Return ->
🥉
Intuitive Surgical
A-Score
1-Year Total Return ->
4
Thermo Fisher
A-Score
1-Year Total Return ->
5
Becton Dickinson
A-Score
1-Year Total Return ->
6
